Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
Introduction and Purpose: Obesity is an escalating global health challenge, affecting over 2 billion individuals worldwide, contributing to many challenges for healthcare providers such as cardiovascular disorders, cancers, and type 2 diabetes mellitus. There is a need for effective treatments targe...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2025-02-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/57712 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823865283765338112 |
|---|---|
| author | Aleksander Jentkiewicz Esmail Haj Obeid Jakub Ulrych Jan Krupa Maciej Malinowski Michał Krasowski Alicja Kalinowska Wiktoria Pietras Adrian Kozieł Zofia Kurek |
| author_facet | Aleksander Jentkiewicz Esmail Haj Obeid Jakub Ulrych Jan Krupa Maciej Malinowski Michał Krasowski Alicja Kalinowska Wiktoria Pietras Adrian Kozieł Zofia Kurek |
| author_sort | Aleksander Jentkiewicz |
| collection | DOAJ |
| description | Introduction and Purpose: Obesity is an escalating global health challenge, affecting over 2 billion individuals worldwide, contributing to many challenges for healthcare providers such as cardiovascular disorders, cancers, and type 2 diabetes mellitus. There is a need for effective treatments targeting T2DM, and obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists developed originally for T2DM treatment, have emerged as key agents for weight loss. This review examines current evidence regarding efficacy, safety, and mechanisms of action of GLP-1 RAs, particularly semaglutide and tirzepatide in obesity and weight loss treatment.
Description of the State of Knowledge: GLP-1 receptor agonists modulate appetite, resulting in lower calory intake. Gastric emptying and insulin secretion are also affected by GLP-1 RAs. Clinical trials consistently demonstrate significant weight loss, positive action on cardiovascular risk and better glycemic control. All GLP-1 RAs have common side effects which are gastrointestinal disorders, and gallbladder-related issues, but their safety profiles are acceptable.
Summary: Available evidence recommends GLP-1 receptor agonists in type 2 diabetes mellitus and obesity treatment. Tirzepatide and semaglutide are two pharmacological agents which show best results in terms of weight loss.
Materials and Evidence: A literature review was conducted using the PubMed database for articles published from January 2016 to January 2024, supplemented by earlier foundational papers. After screening 121 abstracts, 51 full-text articles were assessed, and 30 were ultimately included.
|
| format | Article |
| id | doaj-art-a58fa0b3b49f42ecb66466dafdc9f9be |
| institution | Kabale University |
| issn | 2391-8306 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj-art-a58fa0b3b49f42ecb66466dafdc9f9be2025-02-08T08:18:28ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062025-02-017810.12775/JEHS.2025.78.57712Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature reviewAleksander Jentkiewicz0https://orcid.org/0009-0008-4224-4069Esmail Haj Obeid1https://orcid.org/0009-0008-5165-1221Jakub Ulrych2https://orcid.org/0009-0004-7460-965XJan Krupa3https://orcid.org/0009-0001-2175-806XMaciej Malinowskihttps://orcid.org/0009-0003-7637-6290Michał Krasowskihttps://orcid.org/0009-0006-6243-1246Alicja Kalinowskahttps://orcid.org/0009-0000-9011-843XWiktoria Pietrashttps://orcid.org/0009-0003-2887-8755Adrian Koziełhttps://orcid.org/0009-0006-6096-5850Zofia Kurekhttps://orcid.org/0009-0002-4156-8666Warszawski Uniwersytet MedycznyMedical University of WarsawMedical University of WarsawMedical University of WarsawIntroduction and Purpose: Obesity is an escalating global health challenge, affecting over 2 billion individuals worldwide, contributing to many challenges for healthcare providers such as cardiovascular disorders, cancers, and type 2 diabetes mellitus. There is a need for effective treatments targeting T2DM, and obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists developed originally for T2DM treatment, have emerged as key agents for weight loss. This review examines current evidence regarding efficacy, safety, and mechanisms of action of GLP-1 RAs, particularly semaglutide and tirzepatide in obesity and weight loss treatment. Description of the State of Knowledge: GLP-1 receptor agonists modulate appetite, resulting in lower calory intake. Gastric emptying and insulin secretion are also affected by GLP-1 RAs. Clinical trials consistently demonstrate significant weight loss, positive action on cardiovascular risk and better glycemic control. All GLP-1 RAs have common side effects which are gastrointestinal disorders, and gallbladder-related issues, but their safety profiles are acceptable. Summary: Available evidence recommends GLP-1 receptor agonists in type 2 diabetes mellitus and obesity treatment. Tirzepatide and semaglutide are two pharmacological agents which show best results in terms of weight loss. Materials and Evidence: A literature review was conducted using the PubMed database for articles published from January 2016 to January 2024, supplemented by earlier foundational papers. After screening 121 abstracts, 51 full-text articles were assessed, and 30 were ultimately included. https://apcz.umk.pl/JEHS/article/view/57712tirzepatidesemaglutideweight lossGLP-1 receptor agonistsobesity treatmentliraglutide |
| spellingShingle | Aleksander Jentkiewicz Esmail Haj Obeid Jakub Ulrych Jan Krupa Maciej Malinowski Michał Krasowski Alicja Kalinowska Wiktoria Pietras Adrian Kozieł Zofia Kurek Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review Journal of Education, Health and Sport tirzepatide semaglutide weight loss GLP-1 receptor agonists obesity treatment liraglutide |
| title | Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review |
| title_full | Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review |
| title_fullStr | Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review |
| title_full_unstemmed | Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review |
| title_short | Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review |
| title_sort | glucagon like peptide 1 receptor agonists in obesity treatment a literature review |
| topic | tirzepatide semaglutide weight loss GLP-1 receptor agonists obesity treatment liraglutide |
| url | https://apcz.umk.pl/JEHS/article/view/57712 |
| work_keys_str_mv | AT aleksanderjentkiewicz glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT esmailhajobeid glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT jakubulrych glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT jankrupa glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT maciejmalinowski glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT michałkrasowski glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT alicjakalinowska glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT wiktoriapietras glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT adriankozieł glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview AT zofiakurek glucagonlikepeptide1receptoragonistsinobesitytreatmentaliteraturereview |